4.2 Article

Characteristics of magnetic resonance imaging biomarkers in a natural history study of golden retriever muscular dystrophy

Journal

NEUROMUSCULAR DISORDERS
Volume 24, Issue 2, Pages 178-191

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2013.10.005

Keywords

Biomarker; GRMD; MRI; Muscular dystrophy; Texture analysis; T2 mapping

Funding

  1. National Institutes of Health (NINDS) (Styner) [R42 NS059095-03, P30-HD003110-41]
  2. National Institutes of Health (NINDS) (Kornegay) [1U24NS059696-01A1]
  3. Muscular Dystrophy Association (Kornegay), Wellstone Center for Muscular Dystrophy Research [USPHS (NIAMS)] [1U54AR056953-01]
  4. North Carolina Translational and Clinical Sciences (NC TraCS) Institute (Fan) [Tracs50 K (50KR71104)]
  5. UNC Intellectual and Developmental Disabilities Research Center [P30 HD03110]

Ask authors/readers for more resources

The goal of this study was to assess whether magnetic resonance imaging (MRI) biomarkers can quantify disease progression in golden retriever muscular dystrophy (GRMD) via a natural history study. The proximal pelvic limbs of ten GRMD and eight normal dogs were scanned at 3, 6, and 9-12 months of age. Several MRI imaging and texture analysis biomarkers were quantified in seven muscles. Almost all MRI biomarkers readily distinguished GRMD from control dogs; however, only selected biomarkers tracked with longitudinal disease progression. The biomarkers that performed best were full-length muscle volume and a texture analysis biomarker, termed heterogeneity index. The biceps femoris, semitendinosus and cranial sartorius muscles showed differential progression in GRMD versus control dogs. MRI features in GRMD dogs showed dynamic progression that was most pronounced over the 3- to 6-month period. Volumetric biomarkers and water map values correlated with histopathological features of necrosis/regeneration at 6-months. In conclusion, selected MRI biomarkers (volume and heterogeneity index) in particular muscles (biceps femoris, semitendinosus, and cranial sartorius) adjusted for age effect allow distinction of differential longitudinal progression in GRMD dogs. These biomarkers may be used as surrogate outcome measures in preclinical GRMD trials. (C) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available